SCHEMBL5026675

SCHEMBL5026675

Fc1cccc(-c2csc(Nc3ccc(C(F)(F)F)cc3)n2)c1

nearest known ligand 0.64

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 2/20 0.64
CFTR P13569 2/20 0.64
NPY5R Q15761 2/20 0.59
CYP1A1 P04798 4/20 0.57
CYP1A2 P05177 4/20 0.57
CYP1B1 Q16678 4/20 0.57
MAPT P10636 7/20 0.56
RAB9A P51151 2/20 0.56
SMN1; SMN2 Q16637 2/20 0.56
POLB P06746 2/20 0.56
NPC1 O15118 1/20 0.56
TDP1 Q9NUW8 1/20 0.56
VCP P55072 2/20 0.56
MAPK1 P28482 2/20 0.55
MEN1 O00255 2/20 0.54
KMT2A Q03164 2/20 0.54
KDM4E B2RXH2 3/20 0.53
NAMPT P43490 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31126438 1.00 ALOX5 (0.64) ALOX5CFTRNPY5RCYP1A1CYP1A2
SCHEMBL12157846 0.89 VCP (0.71) ALOX5CFTRNPY5RCYP1A1CYP1A2
SCHEMBL23539595 0.86 ALOX5 (0.73) ALOX5CFTRNPY5RCYP1A1CYP1A2
SCHEMBL5022850 0.85 CYP1A1 (0.74) ALOX5NPY5RCYP1A1CYP1A2CYP1B1
SCHEMBL1822809 0.85 ALOX5 (0.76) ALOX5CFTRNPY5RCYP1A1CYP1A2
SCHEMBL12158244 0.84 CYP1A1 (0.57) ALOX5CFTRCYP1A1CYP1A2CYP1B1
SCHEMBL31126428 0.84 ALOX5 (0.78) ALOX5NPY5RCYP1A1CYP1A2CYP1B1
SCHEMBL23742597 0.84 CYP1A1 (0.76) ALOX5CFTRNPY5RCYP1A1CYP1A2
SCHEMBL12157973 0.84 ALOX5 (0.73) ALOX5CFTRNPY5RMAPTRAB9A
SCHEMBL23539933 0.82 CSNK2A1 (0.76) ALOX5CFTRMAPTRAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1261607-B1 2,4-DISUBSTITUTED THIAZOLYL DERIVATIVES JANSSEN PHARMACEUTICA NV (BE) 2008-11-12 EP claimed
EP-1926719-B1 2-ANILINE-4-ARYL SUBSTITUTED THIAZOLE DERIVATIVES JANSSEN PHARMACEUTICA NV (BE) 2017-05-31 EP disclosed
US-9388175-B2 2-aniline-4-aryl substituted thiazole derivatives JANSSEN PHARMACEUTICA N.V. (BE) 2016-07-12 US disclosed
US-9388175-B2 2-aniline-4-aryl substituted thiazole derivatives JANSSEN PHARMACEUTICA N.V. (BE) 2016-07-12 US disclosed
US-20110269748-A1 2-ANILINE-4-ARYL SUBSTITUTED THIAZOLE DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 2011-11-03 US disclosed
US-20110269748-A1 2-ANILINE-4-ARYL SUBSTITUTED THIAZOLE DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 2011-11-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110269748-A1 2-ANILINE-4-ARYL SUBSTITUTED THIAZOLE DERIVATIVES CHRNA4, CHRNA5, CHRNA7 ALOX5 49/4885CFTR 429/4885NPY5R 179/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.